ArticleCancer medicine2024

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.

Megan H Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.